US basedUS hosted
Desks
$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.the modern leap
Health / Medical Research

Eversense 365 and iLet Bionic Pancreas Launch Together

Senseonics and Beta Bionics launched the integrated Eversense 365 and iLet Bionic Pancreas system commercially on November 16, 2026. The pairing joins a continuous glucose sensor that runs for a full year from a single implanted sensor with a fully adaptive automated insulin delivery system, so the two halves of diabetes management — measuring glucose and dosing insulin — now run as one system with far fewer device changes than patients are used to.

A continuous glucose monitor applicator (archive). The Eversense 365 sensor is implanted under the skin and reports glucose for a full year, feeding the iLet system's automated insulin dosing. Photo: Vasmar1, CC BY-SA 4.0, via Wikimedia Commons.
Summary

Diabetes technology usually asks patients to manage two devices on two schedules. This launch puts a year-long sensor and an adaptive pump on the same team, and the next test is whether clinics and insurers move as fast as the engineering did.

Tap a passage. React to the part that matters.

A glucose sensor that lasts a year is now driving an insulin pump that doses on its own. Senseonics Holdings and Beta Bionics announced the commercial launch of the iLet Bionic Pancreas integrated with the Eversense 365 continuous glucose monitoring system on November 16, 2026, joining the two devices into a single automated insulin delivery system for people with diabetes.

The division of labor is the story. Eversense 365, made by Senseonics of Germantown, Maryland, delivers one year of glucose monitoring from a single sensor — an implanted sensor, not a wearable patch — and the companies say it stays accurate even at low glucose levels, the range where a wrong reading carries the most risk. The iLet, made by Beta Bionics of Irvine, California, is the dosing half: a fully adaptive system that adjusts insulin delivery automatically from the glucose data it receives.

Automated insulin delivery only works as well as the data feeding it, and it only relieves the burden it's supposed to relieve if patients aren't constantly maintaining the hardware. That's where the one-year figure does its work. Most glucose sensors in use today are replaced in days or weeks, and every replacement is a small procedure, a cost and a chance for a gap in the data. A sensor that runs twelve months turns the sensor from a recurring chore into an annual appointment.

The launch also closes a schedule the companies set in public. Senseonics and Beta Bionics announced their partnership in September 2026 and committed to launching the integrated system in the fourth quarter of 2026. Monday's announcement lands inside that window, which matters in a device market where integration timelines routinely slip — an insulin system is only a system when both halves are actually shipping together.

The companies have already named the next integration. They've committed to connecting Eversense 365 with Mint, Beta Bionics' tubeless patch pump, in the future — a version of the same pairing for patients who don't want a tubed pump. No date was given for that launch, and the companies provided no pricing or insurance-coverage details in Monday's announcement, which leaves the two questions patients ask first — what does it cost, and will my plan pay for it — for the rollout itself.

What to watch now is adoption, not engineering. A year-long implanted sensor requires a clinician to place it and remove it, so the system's reach depends on how many diabetes practices build that procedure into their routine, and on whether payers treat the pairing as standard automated delivery or as something newer that needs separate justification. The technology argument is settled by the launch. The access argument starts now.

The pairing also reflects where diabetes care has been heading for a decade: from fingersticks and manual dose math toward systems that sense and respond continuously, asking the patient to supervise rather than operate. Each integration like this one removes a handoff — a reading taken here, a dose decided there — and every removed handoff is one less place for the daily management of a lifelong disease to break down.

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.